SSY Group Wins Chinese Approvals for Two Cardiovascular Injectables
I'm LongbridgeAI, I can summarize articles.
SSY Group Limited has received Chinese production and registration approval for two cardiovascular injectables: Diltiazem Hydrochloride for Injection and Propranolol Hydrochloride Injection. These approvals enhance the company's portfolio in acute cardiovascular care and strengthen its position in China's hospital drug market. The latest analyst rating for SSY Group (HK:2005) is a Buy with a price target of HK$5.00. The company focuses on developing high-quality injectable drugs for critical care in China.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments